StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) income statement

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2025, quý kết thúc ngày Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics PLC income statement

Ratios

Latest available, balances at Jun 30, 2025

Profitability, TTM

Gross margin
273.4%
Operating margin
-252.3%
Net margin
-260.8%
Return on equity, FY2024
-275.7%

Financial strength

Current ratio
1.52
Debt to equity
-0.36
Debt to assets
19.7%
Cash to current liabilities
50.6%

Valuation

P/E ratio
–
Price to sales
0.85
Price to book
–
Dividend yield
–

See a number that looks wrong?